| Dr Jennifer Leigh Armijo, FNP-C | |
|
5700 Williamsburg Landing Dr, Williamsburg, VA 23185-3779 | |
| (800) 554-5517 | |
| Not Available |
| Full Name | Dr Jennifer Leigh Armijo |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 5700 Williamsburg Landing Dr, Williamsburg, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285282368 | NPI | - | NPPES |
| Provider Name | Velocity Urgent Care Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1205350584 PECOS PAC ID: 7618234980 Enrollment ID: O20171122001472 |
News Archive
A new study published in the June issue of Journal of Alzheimer's Disease demonstrates the accuracy and validity of a new mathematics-based memory assessment developed by Medical Care Corporation to detect early signs of memory impairment due to Alzheimer's disease and other related disorders.
A culture of 'secrecy and silence' clouds the true picture of AIDS related deaths among doctors in South Africa, says Dr Dan Ncayiyana, editor of the South African Medical Journal, in this week's BMJ.
For the first time, national authorities carrying out official food allergen controls have a common basis for accepting validated testing methods. Consumers allergic to certain food ingredients will benefit from an increased level of protection by the availability of harmonised and reliable testing methods, and international trade will be facilitated by applying mutually-agreed testing protocols.
Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist. If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.
› Verified 2 days ago
| Provider Name | Mid-atlantic Post Acute & Long Term Care Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1225557556 PECOS PAC ID: 0648530782 Enrollment ID: O20180209000313 |
News Archive
A new study published in the June issue of Journal of Alzheimer's Disease demonstrates the accuracy and validity of a new mathematics-based memory assessment developed by Medical Care Corporation to detect early signs of memory impairment due to Alzheimer's disease and other related disorders.
A culture of 'secrecy and silence' clouds the true picture of AIDS related deaths among doctors in South Africa, says Dr Dan Ncayiyana, editor of the South African Medical Journal, in this week's BMJ.
For the first time, national authorities carrying out official food allergen controls have a common basis for accepting validated testing methods. Consumers allergic to certain food ingredients will benefit from an increased level of protection by the availability of harmonised and reliable testing methods, and international trade will be facilitated by applying mutually-agreed testing protocols.
Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist. If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.
› Verified 2 days ago
| Provider Name | Pai Participant 1 Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1093371312 PECOS PAC ID: 8123351954 Enrollment ID: O20211208001934 |
News Archive
A new study published in the June issue of Journal of Alzheimer's Disease demonstrates the accuracy and validity of a new mathematics-based memory assessment developed by Medical Care Corporation to detect early signs of memory impairment due to Alzheimer's disease and other related disorders.
A culture of 'secrecy and silence' clouds the true picture of AIDS related deaths among doctors in South Africa, says Dr Dan Ncayiyana, editor of the South African Medical Journal, in this week's BMJ.
For the first time, national authorities carrying out official food allergen controls have a common basis for accepting validated testing methods. Consumers allergic to certain food ingredients will benefit from an increased level of protection by the availability of harmonised and reliable testing methods, and international trade will be facilitated by applying mutually-agreed testing protocols.
Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist. If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.
› Verified 2 days ago
| Provider Name | Williamsburg Landing Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1457096406 PECOS PAC ID: 5890854186 Enrollment ID: O20220818000409 |
News Archive
A new study published in the June issue of Journal of Alzheimer's Disease demonstrates the accuracy and validity of a new mathematics-based memory assessment developed by Medical Care Corporation to detect early signs of memory impairment due to Alzheimer's disease and other related disorders.
A culture of 'secrecy and silence' clouds the true picture of AIDS related deaths among doctors in South Africa, says Dr Dan Ncayiyana, editor of the South African Medical Journal, in this week's BMJ.
For the first time, national authorities carrying out official food allergen controls have a common basis for accepting validated testing methods. Consumers allergic to certain food ingredients will benefit from an increased level of protection by the availability of harmonised and reliable testing methods, and international trade will be facilitated by applying mutually-agreed testing protocols.
Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist. If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.
› Verified 2 days ago
| Provider Name | Se Virginia Value Based Care Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1225720501 PECOS PAC ID: 6103288170 Enrollment ID: O20230809000204 |
News Archive
A new study published in the June issue of Journal of Alzheimer's Disease demonstrates the accuracy and validity of a new mathematics-based memory assessment developed by Medical Care Corporation to detect early signs of memory impairment due to Alzheimer's disease and other related disorders.
A culture of 'secrecy and silence' clouds the true picture of AIDS related deaths among doctors in South Africa, says Dr Dan Ncayiyana, editor of the South African Medical Journal, in this week's BMJ.
For the first time, national authorities carrying out official food allergen controls have a common basis for accepting validated testing methods. Consumers allergic to certain food ingredients will benefit from an increased level of protection by the availability of harmonised and reliable testing methods, and international trade will be facilitated by applying mutually-agreed testing protocols.
Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist. If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jennifer Leigh Armijo, FNP-C 6160 Kempsville Cir Ste 325a, Norfolk, VA 23502-3933 Ph: () - | Dr Jennifer Leigh Armijo, FNP-C 5700 Williamsburg Landing Dr, Williamsburg, VA 23185-3779 Ph: (800) 554-5517 |
News Archive
A new study published in the June issue of Journal of Alzheimer's Disease demonstrates the accuracy and validity of a new mathematics-based memory assessment developed by Medical Care Corporation to detect early signs of memory impairment due to Alzheimer's disease and other related disorders.
A culture of 'secrecy and silence' clouds the true picture of AIDS related deaths among doctors in South Africa, says Dr Dan Ncayiyana, editor of the South African Medical Journal, in this week's BMJ.
For the first time, national authorities carrying out official food allergen controls have a common basis for accepting validated testing methods. Consumers allergic to certain food ingredients will benefit from an increased level of protection by the availability of harmonised and reliable testing methods, and international trade will be facilitated by applying mutually-agreed testing protocols.
Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist. If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.
› Verified 2 days ago